Boomer Esiason’s commitment to enhancing the quality of life for cystic fibrosis sufferers has become the stuff of legend. Add Teaser here
Featured
Federal Issues UNITEDHEALTH GROUP: UnitedHealth Group Statement on Trump Administration’s Drug Policy Proposal
Industry News PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION: American Diabetes Association White Paper Confirms Drugmakers Set and Raise Insulin Prices
Latest News
Industry News SANDOZ: Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis
Industry News ABBVIE: AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
Federal Issues
- PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION: Congressional Budget Office Score of Medicare Point-of-Sale Rebates Undermines Drugmakers’ Signature Issue
- U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES: HHS Secretary Azar Praises FDA Approval of First Non-Opioid Treatment for Opioid Withdrawal
- DISTRICT ATTORNEY WEST VIRGINIA: Mullens Doctor Charged in 20 Count Indictment With Unlawful Distribution of Prescription Opioids and Health Care Fraud
- THE RITE AID CORPORATION: Rite Aid Makes Free Opioid Disposal Solution Available At More Than 2,500 Pharmacies Nationwide
Industry News
- BRISTOL-MYERS SQUIB: Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma
- ABBVIE: AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
- TEVA: Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache
- ASTRAZENECA PHARMACEUTICALS LP: Update on Phase III clinical trials of lanabecestat for Alzheimer’s disease
Innovation
- BAXTER: Baxter Announces U.S. FDA Clearance of New Spectrum IQ Infusion System
- ELI LILLY AND COMPANY: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
- GILEAD SCIENCES, INC: U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
- GENENTECH, INC:Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) and COTELLIC (Cobimetinib) in People With Heavily Pre-Treated Locally Advanced or Metastatic Colorectal Cancer
Regulatory
- SUNOVION PHARMACEUTICALS INC: Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)
- MERCK: FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for GARDASIL®9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases
- GENENTECH,INC: FDA Approves Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris
- PFIZER: U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
Alerts Sign-up